Table 1.

Patient characteristics and clinical evaluations at baseline.

Patient	Age	Gender	Lesion site	Affected Arm	t0 (days)	BI	FMA-UL MF	FMA–UL PjM	FMA–UL P	FMA–UL SF	FMA–UL Tot	WMFT score	WMFT time (sec.)
1	54	M	CS	L	31	5	6	22	22	7	57	6	1451
2	65	M	CS	L	15	5	5	22	20	2	49	4	1568
3	79	F	CS	R	23	30	56	24	24	NV	104	65	70
4	85	M	CS	R	45	0	2	21	24	NV	47	0	1800
5	76	M	CS	R	26	25	4	20	24	11	59	0	1800
6	80	F	CS	R	45	5	18	22	24	6	70	19	1050
7	77	F	CS	L	14	10	4	24	24	6	58	0	1800
8	59	M	CS	L	19	90	51	24	23	11	109	66	98.21
9	73	F	CS	L	34	10	45	19	24	9	97	50	120
10	61	F	CS	R	14	85	62	24	24	7	94	74	52.91
11	54	M	S	L	22	35	17	23	21	9	70	38	370
12	59	M	S	R	45	10	8	22	20	NV	50	0	1800
13	78	M	S	R	19	30	52	24	20	12	108	74	52
14	63	M	S	L	19	30	19	22	24	12	77	16	897
15	65	M	S	R	32	35	21	21	23	12	77	29	482
16	22	M	S	R	21	95	62	24	24	12	122	66	39
17	82	F	S	L	27	20	48	22	24	12	106	58	104
18	52	M	S	R	15	100	65	24	24	12	125	67	38
19	73	M	S	L	11	55	40	24	22	11	97	60	64
20	80	M	S	L	18	20	9	23	24	11	65	4	1457

General characteristics of each patient: age, gender, lesion location (Cortico-subcortical, CS, or purely subcortical, S), affected arm and number of days between the acute event and baseline evaluation (T0). Clinical assessment: BI (Barthel Index); FMA -UL (Fugl-Meyer Assessment for upper limb motor function) Total score (Tot) and sub scores of Motor function (MF), Passive joint motion (PJM), Pain (P), and Sensory function (SF); WMFT (Wolf Motor Function Test) Score and Time.